A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
NCT ID: NCT02688647
Last Updated: 2022-09-08
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
76 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-05-26
Study Completion Date
2021-04-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized female subjects with Idiopathic Pulmonary Fibrosis (IPF). The primary objectives are to evaluate the:
* Change in Forced Vital Capacity (FVC) from baseline to 24 weeks after dosing with belumosudil 400 mg PO QD in subjects with IPF compared to BSC
* Safety and tolerability of belumosudil 400 mg PO QD when administered for 24 weeks to subjects with IPF compared to BSC
* Change in Forced Vital Capacity (FVC) from baseline to 24 weeks after dosing with belumosudil 400 mg PO QD in subjects with IPF compared to BSC
* Safety and tolerability of belumosudil 400 mg PO QD when administered for 24 weeks to subjects with IPF compared to BSC
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426
Idiopathic Pulmonary Fibrosis
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Progressive Pulmonary Fibrosis
ACTIVE_NOT_RECRUITING
PHASE3
Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis
NCT05976217
Idiopathic Pulmonary Fibrosis
COMPLETED
EARLY_PHASE1
A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease
NCT00219622
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE2
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
NCT03142191
Idiopathic Pulmonary Fibrosis
Fibrosis
Idiopathic Interstitial Pneumonias
+4 more
TERMINATED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study KD025-207 is a Phase 2, randomized, 2-part, open-label, crossover study in subjects with IPF.
The purpose of the study is to evaluate the safety, tolerability, and activity of 400 mg of belumosudil administered orally (PO) every day (QD) compared to Best Standard of Care (BSC) in subjects with IPF who have previously been treated with or declined treatment with pirfenidone or nintedanib.
The primary objectives are to evaluate the change in Forced Vital Capacity (FVC), and the safety and tolerability from baseline to 24 weeks in subjects with IPF after dosing with belumosudil 400 mg PO QD compared to BSC.
Part 1: Randomized, Open-label for 24 Weeks
Approximately 81 eligible subjects with IPF are to be enrolled, in 10 to 15 sites, and randomized in a 2:1 ratio (belumosudil:BSC) to 1 of the following 2 groups:
* Belumosudil-R (Investigational Group): Belumosudil 400 mg PO QD for 24 weeks
* BSC-R (Control Group): BSC for 24 weeks
The study plan is for 54 subjects to be entered into the Belumosudil-R Treatment Group and 27 subjects into the BSC-R Treatment Group. This sample size provides over 90% power at the 2-sided 0.05 significance level to detect a 20% difference between treatment groups at 24 weeks in percentage change from baseline in FVC assuming a standard deviation (SD) in percentage change from baseline in FVC of 17%. The sample size of 54 subjects receiving belumosudil provides over 90% probability of ≥ 1 subject in the study experiencing an AE that had an underlying rate of ≥ 5%.
Part 2: Continuation of Belumosudil Therapy or Crossover to Belumosudil Therapy Subjects in the Belumosudil-R group who complete 24 weeks of treatment with belumosudil 400 mg PO QD have the option of continuing therapy with belumosudil 400 mg PO QD up to an additional 72 weeks if there are no safety signals and if clinical progress continues. No subject in the Belumosudil-R group is to be permitted to receive therapy with belumosudil greater than a total of 96 weeks.
Subjects in control group BSC-R who complete 24 weeks of BSC have the option of crossing over to therapy with belumosudil 400 mg PO QD for up to 96 weeks if there are no safety signals and if clinical progress continues. No subject in control group BSC-R is to be permitted to receive belumosudil 400 mg PO QD therapy greater than 96 weeks.
Follow-up Period:
Follow-up Visits are to occur 30 days (± 3 days) after the last dose of belumosudil during which subjects are to undergo safety assessments. (A Follow-up Visit is not necessary for subjects receiving BSC.)
Duration of Study for Individual Subjects:
1. Subjects randomized to belumosudil: total up to 104 weeks (4-week screening, 96-week treatment with belumosudil, and 4-week follow-up)
2. Subject randomized to BSC: total up to 128 weeks (4-week screening; up to 24-week treatment with BSC, 96-week treatment with belumosudil, and 4-week follow-up)
Efficacy Assessments
* FVC
* FVC% Predicted
* 6-minute Walking Distance (6MWD)
* Diffusing Capacity of Carbon Monoxide (DLCO)
* Lung Fibrosis (by HRCT and Radiologist's Visual Assessments)
* Time to Acute Exacerbation
* Time to Progression of IPF
* Time to Respiratory-related Hospitalization
* Time to Respiratory-related Death
* St. Georges Respiratory Questionnaire (SGRQ)
Biomarker Assessments
* Matrix Metalloproteinase-7 (MMP7)
* Chemokine Ligand 18 (CCL18)
* Surfactant Protein-D (SPD)
Safety Assessments
* Adverse event (AE)
* Serious adverse event (SAE)
* Physical examination (PE)
* Vital signs (VS)
* Clinical laboratory evaluations (hematology, chemistry, and urinalysis)
* Electrocardiogram (ECG)
* Reason for treatment discontinuation due to toxicity
Analyses
Efficacy and safety are to be analyzed at the end of Part 1 (Week 24) and for the Entire Treatment Period (Parts 1 and 2). Analyses of study subjects are to be grouped and defined as follows:
* Belumosudil-R: subjects randomized to belumosudil
* BSC-R: subjects randomized to BSC
* Belumosudil-WC: subjects randomized to belumosudil plus subjects randomized to BSC and who cross over to treatment with belumosudil
* BSC-NC: subjects randomized to BSC and who cross over to treatment with belumosudil but have data censored by the date of crossover
The purpose of the study is to evaluate the safety, tolerability, and activity of 400 mg of belumosudil administered orally (PO) every day (QD) compared to Best Standard of Care (BSC) in subjects with IPF who have previously been treated with or declined treatment with pirfenidone or nintedanib.
The primary objectives are to evaluate the change in Forced Vital Capacity (FVC), and the safety and tolerability from baseline to 24 weeks in subjects with IPF after dosing with belumosudil 400 mg PO QD compared to BSC.
Part 1: Randomized, Open-label for 24 Weeks
Approximately 81 eligible subjects with IPF are to be enrolled, in 10 to 15 sites, and randomized in a 2:1 ratio (belumosudil:BSC) to 1 of the following 2 groups:
* Belumosudil-R (Investigational Group): Belumosudil 400 mg PO QD for 24 weeks
* BSC-R (Control Group): BSC for 24 weeks
The study plan is for 54 subjects to be entered into the Belumosudil-R Treatment Group and 27 subjects into the BSC-R Treatment Group. This sample size provides over 90% power at the 2-sided 0.05 significance level to detect a 20% difference between treatment groups at 24 weeks in percentage change from baseline in FVC assuming a standard deviation (SD) in percentage change from baseline in FVC of 17%. The sample size of 54 subjects receiving belumosudil provides over 90% probability of ≥ 1 subject in the study experiencing an AE that had an underlying rate of ≥ 5%.
Part 2: Continuation of Belumosudil Therapy or Crossover to Belumosudil Therapy Subjects in the Belumosudil-R group who complete 24 weeks of treatment with belumosudil 400 mg PO QD have the option of continuing therapy with belumosudil 400 mg PO QD up to an additional 72 weeks if there are no safety signals and if clinical progress continues. No subject in the Belumosudil-R group is to be permitted to receive therapy with belumosudil greater than a total of 96 weeks.
Subjects in control group BSC-R who complete 24 weeks of BSC have the option of crossing over to therapy with belumosudil 400 mg PO QD for up to 96 weeks if there are no safety signals and if clinical progress continues. No subject in control group BSC-R is to be permitted to receive belumosudil 400 mg PO QD therapy greater than 96 weeks.
Follow-up Period:
Follow-up Visits are to occur 30 days (± 3 days) after the last dose of belumosudil during which subjects are to undergo safety assessments. (A Follow-up Visit is not necessary for subjects receiving BSC.)
Duration of Study for Individual Subjects:
1. Subjects randomized to belumosudil: total up to 104 weeks (4-week screening, 96-week treatment with belumosudil, and 4-week follow-up)
2. Subject randomized to BSC: total up to 128 weeks (4-week screening; up to 24-week treatment with BSC, 96-week treatment with belumosudil, and 4-week follow-up)
Efficacy Assessments
* FVC
* FVC% Predicted
* 6-minute Walking Distance (6MWD)
* Diffusing Capacity of Carbon Monoxide (DLCO)
* Lung Fibrosis (by HRCT and Radiologist's Visual Assessments)
* Time to Acute Exacerbation
* Time to Progression of IPF
* Time to Respiratory-related Hospitalization
* Time to Respiratory-related Death
* St. Georges Respiratory Questionnaire (SGRQ)
Biomarker Assessments
* Matrix Metalloproteinase-7 (MMP7)
* Chemokine Ligand 18 (CCL18)
* Surfactant Protein-D (SPD)
Safety Assessments
* Adverse event (AE)
* Serious adverse event (SAE)
* Physical examination (PE)
* Vital signs (VS)
* Clinical laboratory evaluations (hematology, chemistry, and urinalysis)
* Electrocardiogram (ECG)
* Reason for treatment discontinuation due to toxicity
Analyses
Efficacy and safety are to be analyzed at the end of Part 1 (Week 24) and for the Entire Treatment Period (Parts 1 and 2). Analyses of study subjects are to be grouped and defined as follows:
* Belumosudil-R: subjects randomized to belumosudil
* BSC-R: subjects randomized to BSC
* Belumosudil-WC: subjects randomized to belumosudil plus subjects randomized to BSC and who cross over to treatment with belumosudil
* BSC-NC: subjects randomized to BSC and who cross over to treatment with belumosudil but have data censored by the date of crossover
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Idiopathic Pulmonary Fibrosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
In Part 1: Subjects are randomized to treatment with either Belumosudil 400 mg PO QD (Belumosudil-R) or to BSC (BSC-R).
In Part 2: Subjects who are randomized and receive Belumosudil 400 mg PO QD during Part 1 have the option to continue treatment with Belumosudil 400 mg PO QD and subjects randomized to BSC have the option to cross over to treatment with Belumosudil 400 mg PO QD.
No subject is permitted \> 96 weeks of treatment with belumosudil
In Part 2: Subjects who are randomized and receive Belumosudil 400 mg PO QD during Part 1 have the option to continue treatment with Belumosudil 400 mg PO QD and subjects randomized to BSC have the option to cross over to treatment with Belumosudil 400 mg PO QD.
No subject is permitted \> 96 weeks of treatment with belumosudil
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Belumosudil-R
Subjects receive two 200 mg tablets of belumosudil (400 mg) PO QD for 24 weeks. Subjects may also continue treatment with belumosudil 400 mg PO QD after 24 weeks.
No subject may receive more than 96 weeks of treatment with belumosudil
Group Type
EXPERIMENTAL
Belumosudil
Intervention Type
DRUG
BSC-R
Subjects receive best supportive care as determined by the physician. Subjects may later crossover to treatment with belumosudil 400 mg PO QD. No subject may receive more than 96 weeks of treatment with belumosudil.
Group Type
ACTIVE_COMPARATOR
BSC
Intervention Type
OTHER
Treatment/drug as determined by each subject's prescribing physician
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Belumosudil
Intervention Type
DRUG
BSC
Treatment/drug as determined by each subject's prescribing physician
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
KD025
SLx-2119
Best standard of care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
A subject had to meet all of the following criteria to be eligible for the study:
1. Adult male and postmenopausal/surgically sterilized female subjects at least 18 years of age (if female, was surgically sterilized \[i.e., total hysterectomy, or bilateral salpingo-oophorectomy\]).
2. Able to provide written informed consent before the performance of any study specific procedures.
3. IPF diagnosis within 5 years before study entry, proven according to the American Thoracic Society/European Respiratory Society consensus conference criteria, with surgical lung biopsy. In the absence of a surgical lung biopsy, high-resolution computerized tomography (HRCT) consistent with usual interstitial pneumonitis.
4. Resting state pulse oximeter oxygen saturation (SpO2) ≥ 88% with or without supplemental oxygen, Forced Vital Capacity % (FVC%) ≥ 50% normal predicted value, and diffusing capcity (in the lung) of carbon monoxide (DLCO) ≥ 30% normal predicted value at baseline.
5. Men with partners of childbearing potential willing to use 2 medically acceptable methods of contraception during the trial and for 3 months after the last dose of study drug. Effective birth control includes:
1. Intrauterine device plus 1 barrier method
2. Stable doses of hormonal contraception for ≥ 3 months (e.g., oral, injectible, implant, transdermal) plus 1 barrier method
3. 2 barrier methods. Effective barrier methods were male or female condoms, diaphragms, and spermicides (creams or gels containing a chemical to kill sperm)
4. Vasectomy.
6. Have adequate bone marrow function:
1. Absolute neutrophil count \> 1500/mm\^3
2. Hemoglobin (Hb) \> 9.0 g/L
3. Platelets \> 100,000/mm\^3
7. Willing to complete all study measurements and assessments in compliance with protocol
8. Had either received pirfenidone and/or nintedanib or offered both treatments (with last dose administered at least 1 month before the expected start of study drug dosing). If either or both pirfenidone and nintedanib treatment had not been given, then documentation that the subject was offered both treatments must have been documented.
1. Adult male and postmenopausal/surgically sterilized female subjects at least 18 years of age (if female, was surgically sterilized \[i.e., total hysterectomy, or bilateral salpingo-oophorectomy\]).
2. Able to provide written informed consent before the performance of any study specific procedures.
3. IPF diagnosis within 5 years before study entry, proven according to the American Thoracic Society/European Respiratory Society consensus conference criteria, with surgical lung biopsy. In the absence of a surgical lung biopsy, high-resolution computerized tomography (HRCT) consistent with usual interstitial pneumonitis.
4. Resting state pulse oximeter oxygen saturation (SpO2) ≥ 88% with or without supplemental oxygen, Forced Vital Capacity % (FVC%) ≥ 50% normal predicted value, and diffusing capcity (in the lung) of carbon monoxide (DLCO) ≥ 30% normal predicted value at baseline.
5. Men with partners of childbearing potential willing to use 2 medically acceptable methods of contraception during the trial and for 3 months after the last dose of study drug. Effective birth control includes:
1. Intrauterine device plus 1 barrier method
2. Stable doses of hormonal contraception for ≥ 3 months (e.g., oral, injectible, implant, transdermal) plus 1 barrier method
3. 2 barrier methods. Effective barrier methods were male or female condoms, diaphragms, and spermicides (creams or gels containing a chemical to kill sperm)
4. Vasectomy.
6. Have adequate bone marrow function:
1. Absolute neutrophil count \> 1500/mm\^3
2. Hemoglobin (Hb) \> 9.0 g/L
3. Platelets \> 100,000/mm\^3
7. Willing to complete all study measurements and assessments in compliance with protocol
8. Had either received pirfenidone and/or nintedanib or offered both treatments (with last dose administered at least 1 month before the expected start of study drug dosing). If either or both pirfenidone and nintedanib treatment had not been given, then documentation that the subject was offered both treatments must have been documented.
Exclusion Criteria
A subject who met any of the following criteria was ineligible for the study:
1. Interstitial lung disease caused by conditions other than IPF
2. Severe concomitant illness limiting life expectancy (\< 1 year)
3. DLCO \< 30% predicted
4. Residual volume (RV) ≥ 120% predicted
5. Obstructive lung disease: Forced Expiratory Volume in 1 Second (FEV1/FVC ratio \< 0.70)
6. Documented sustained improvement of the subject's IPF condition up to 12 months before study entry with or without IPF-specific therapy
7. Pulmonary infection or upper respiratory tract infection (URTI) within 4 weeks before study entry
8. Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements (e.g., pulmonary function tests \[PFTs\])
9. Chronic heart failure with New York Heart Association Class III/IV or known left ventricular ejection fraction \< 25%
10. Moderate to severe hepatic impairment (i.e., Child-Pugh Class B or C)
11. Estimated creatinine clearance \< 30 mL/min
12. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2.0 \* upper limit of normal (ULN)
13. Hb \< 75% of the lower limit of normal
14. Systolic blood pressure \< 100 mmHg
15. Pregnant or breastfeeding female subject
16. Men whose partner is pregnant or breastfeeding
17. Current drug or alcohol dependence
18. Chronic treatment with the following drugs within 4 weeks of study entry and during the study:
1. Immunosuppressive or cytotoxic drugs including cyclophosphamide and azathioprine
2. Antifibrotic drugs including pirfenidone, nintedanib, D-penicillamine, colchicine, tumor necrosis factor-alpha blockers, imatinib, and interferon-γ
3. Chronic use of N-acetylcysteine prescribed for IPF (\> 600 mg/day)
4. Oral anticoagulants prescribed for IPF
19. Treatment with endothelin receptor antagonists within 4 weeks before study entry
20. Systemic treatment within 4 weeks before study entry with cyclosporine A or tacrolimus, everolimus, or sirolimus (calcineurin or mammalian target of rapamycin inhibitors)
21. Previous exposure to belumosudil or known allergy/sensitivity to belumosudil or any other Rho-associated protein kinase 2 (ROCK2) inhibitor
22. Planned treatment or treatment with another investigational drug within 4 weeks before study entry
23. Taking a medication with the potential for QTc prolongation
24. Taking a drug sensitive substrate of CYP enzymes
25. Taking a strong inducer of CYP3A4
26. Had consumed an herbal medication (e.g., St. John's Wort) or grapefruit/grapefruit juice within 14 days prior to the Week 1 Day 1 visit
1. Interstitial lung disease caused by conditions other than IPF
2. Severe concomitant illness limiting life expectancy (\< 1 year)
3. DLCO \< 30% predicted
4. Residual volume (RV) ≥ 120% predicted
5. Obstructive lung disease: Forced Expiratory Volume in 1 Second (FEV1/FVC ratio \< 0.70)
6. Documented sustained improvement of the subject's IPF condition up to 12 months before study entry with or without IPF-specific therapy
7. Pulmonary infection or upper respiratory tract infection (URTI) within 4 weeks before study entry
8. Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements (e.g., pulmonary function tests \[PFTs\])
9. Chronic heart failure with New York Heart Association Class III/IV or known left ventricular ejection fraction \< 25%
10. Moderate to severe hepatic impairment (i.e., Child-Pugh Class B or C)
11. Estimated creatinine clearance \< 30 mL/min
12. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2.0 \* upper limit of normal (ULN)
13. Hb \< 75% of the lower limit of normal
14. Systolic blood pressure \< 100 mmHg
15. Pregnant or breastfeeding female subject
16. Men whose partner is pregnant or breastfeeding
17. Current drug or alcohol dependence
18. Chronic treatment with the following drugs within 4 weeks of study entry and during the study:
1. Immunosuppressive or cytotoxic drugs including cyclophosphamide and azathioprine
2. Antifibrotic drugs including pirfenidone, nintedanib, D-penicillamine, colchicine, tumor necrosis factor-alpha blockers, imatinib, and interferon-γ
3. Chronic use of N-acetylcysteine prescribed for IPF (\> 600 mg/day)
4. Oral anticoagulants prescribed for IPF
19. Treatment with endothelin receptor antagonists within 4 weeks before study entry
20. Systemic treatment within 4 weeks before study entry with cyclosporine A or tacrolimus, everolimus, or sirolimus (calcineurin or mammalian target of rapamycin inhibitors)
21. Previous exposure to belumosudil or known allergy/sensitivity to belumosudil or any other Rho-associated protein kinase 2 (ROCK2) inhibitor
22. Planned treatment or treatment with another investigational drug within 4 weeks before study entry
23. Taking a medication with the potential for QTc prolongation
24. Taking a drug sensitive substrate of CYP enzymes
25. Taking a strong inducer of CYP3A4
26. Had consumed an herbal medication (e.g., St. John's Wort) or grapefruit/grapefruit juice within 14 days prior to the Week 1 Day 1 visit
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kadmon Corporation, LLC
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pulmonary Associates, PA
Phoenix, Arizona, United States
Site Status
University of Arizona
Tucson, Arizona, United States
Site Status
UC Davis Medical Center, Division of Pulmonary/CC/SM
Sacramento, California, United States
Site Status
St. Francis Medical Institute
Clearwater, Florida, United States
Site Status
Pulmonary Disease Specialists, PA, d/b/a PDS Research
Kissimmee, Florida, United States
Site Status
Central Florida Pulmonary Group, PA
Orlando, Florida, United States
Site Status
Piedmont Healthcare Pulmonary and Critical Care Research
Austell, Georgia, United States
Site Status
Pulmonix, LLC
Greensboro, North Carolina, United States
Site Status
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Site Status
Medical University of South Carolina
Charleston, South Carolina, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KD025-207
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT02196077
COMPLETED
PHASE2
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
NCT04678206
COMPLETED
PHASE2
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease
NCT02700919
COMPLETED
PHASE2
Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT01266135
TERMINATED
PHASE2
The Effects of Inhaled Budesonide-formoterol-glycopyrronium in Moderate-to-severe COPD
NCT04675463
UNKNOWN
NA
To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT03081247
WITHDRAWN
PHASE3
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT05573464
COMPLETED
PHASE3
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide
NCT01543919
COMPLETED
PHASE2
A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol
NCT04600505
COMPLETED
PHASE1
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT02536508
COMPLETED
PHASE3
Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD
NCT00476099
COMPLETED
PHASE3
A Crossover Study in the Treatment of Patients With COPD
NCT00462540
COMPLETED
PHASE3
Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo
NCT01049360
COMPLETED
PHASE2
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
NCT03345407
TERMINATED
PHASE2
Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.
NCT01541852
COMPLETED
PHASE2
Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease
NCT02249247
COMPLETED
PHASE2
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT02546700
COMPLETED
PHASE2
Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD
NCT02642614
COMPLETED
PHASE1
Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant
NCT05477108
COMPLETED
PHASE1
Study to Evaluate Safety and Efficacy of Inhaled Bimosiamose for the Treatment of Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01108913
COMPLETED
PHASE2
A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.
NCT00519376
COMPLETED
PHASE2